Takeda Pharmaceutical (TKPHF) Receivables - Other (2018 - 2025)

Takeda Pharmaceutical's Receivables - Other history runs 8 years deep, the most recent figure standing at $380.5 million for Q1 2025.

• In Q1 2025, Receivables - Other rose 0.76% year-over-year to $380.5 million; the TTM figure through Mar 2025 stood at $380.5 million (up 0.76% YoY), while the FY2025 annual figure was $381.1 million, down 1.8% from the prior year.
• Receivables - Other was $380.5 million for Q1 2025 at Takeda Pharmaceutical, up from $377.6 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $714.3 million in Q1 2021 to a low of $377.6 million in Q1 2024.
• Historically, Receivables - Other has averaged $542.5 million across 5 years, with a median of $559.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other sank 32.5% in 2024, then gained 0.76% in 2025.
• A 5-year view of Receivables - Other shows it stood at $714.3 million in 2021, then retreated by 4.68% to $680.9 million in 2022, then decreased by 17.84% to $559.4 million in 2023, then tumbled by 32.5% to $377.6 million in 2024, then advanced by 0.76% to $380.5 million in 2025.
• The last three Receivables - Other figures came in at $380.5 million (Q1 2025), $377.6 million (Q1 2024), and $559.4 million (Q1 2023), per Business Quant data.